Gilder Gagnon Howe & Co. LLC Purchases Shares of 22,952 Tempus AI, Inc. (NASDAQ:TEM)

Gilder Gagnon Howe & Co. LLC bought a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 22,952 shares of the company's stock, valued at approximately $775,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Operose Advisors LLC acquired a new position in shares of Tempus AI during the 4th quarter valued at about $25,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after buying an additional 965 shares during the period. NewEdge Advisors LLC acquired a new stake in shares of Tempus AI during the 4th quarter worth $49,000. Finally, First Horizon Advisors Inc. raised its position in shares of Tempus AI by 207.9% in the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after buying an additional 1,108 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Price Performance

NASDAQ TEM traded up $0.18 on Thursday, hitting $51.85. The stock had a trading volume of 6,328,314 shares, compared to its average volume of 5,706,857. The company's 50-day moving average is $48.50 and its two-hundred day moving average is $50.55. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $91.45. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Buying and Selling

In other news, Director Wayne A.I. Frederick sold 3,000 shares of Tempus AI stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the transaction, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. This trade represents a 10.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $60.00, for a total value of $826,200.00. Following the completion of the sale, the chief accounting officer now owns 57,237 shares of the company's stock, valued at approximately $3,434,220. This trade represents a 19.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,505,134 shares of company stock valued at $268,609,285 in the last three months. 27.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Guggenheim restated a "buy" rating on shares of Tempus AI in a report on Tuesday, February 25th. Wolfe Research lowered Tempus AI from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 26th. Piper Sandler lowered their price objective on shares of Tempus AI from $70.00 to $55.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Needham & Company LLC reissued a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research report on Thursday, April 24th. Finally, JPMorgan Chase & Co. downgraded Tempus AI from an "overweight" rating to a "neutral" rating and increased their price target for the company from $50.00 to $55.00 in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Tempus AI currently has a consensus rating of "Moderate Buy" and an average target price of $61.08.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.